Movox

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Fluvoxamine maleate

Available from:

Alphapharm Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

MOVOX

_contains the active ingredient fluvoxamine maleate_
CONSUMER MEDICINE INFORMATION

WHAT IS IN THIS LEAFLET
This leaflet answers some of the
common questions about Movox.
It does not contain all the available
information. It does not take the
place of talking to your doctor or
pharmacist.
All medicines have risks and
benefits. Your doctor has weighed
the risks of you taking Movox
against the benefits expected for you.
IF YOU HAVE ANY CONCERNS ABOUT
TAKING THIS MEDICINE, TALK TO YOUR
DOCTOR OR PHARMACIST.
PLEASE READ THIS LEAFLET CAREFULLY
AND KEEP IT WITH YOUR MEDICINE.
You may need to read it again.
WHAT MOVOX IS USED
FOR
Movox is used to treat:
•
Depression in adults
•
Obsessive Compulsive Disorder
(OCD) in children aged 8 years
and older, adolescents, and adults.
Movox belongs to a group of
medicines called selective serotonin
reuptake inhibitors (SSRIs).
SSRIs are thought to work by acting
on chemicals in the brain called
amines, which are involved in
controlling mood. Movox corrects
this chemical imbalance and helps to
relieve the symptoms of the above
conditions.
TELL YOUR DOCTOR IMMEDIATELY, OR
GO TO THE NEAREST HOSPITAL, IF YOU
HAVE ANY DISTRESSING THOUGHTS OR
EXPERIENCES DURING THE INITIAL
PERIOD OF STARTING MOVOX, OR AT ANY
OTHER TIME.
ALSO, CONTACT YOUR DOCTOR IF YOU
EXPERIENCE ANY WORSENING OF YOUR
DEPRESSION OR OTHER SYMPTOMS AT
ANY TIME DURING YOUR TREATMENT.
Like other medicines of this type,
Movox will not relieve your
symptoms straight away. People
generally start feeling better in a few
weeks or so.
Occasionally, the symptoms of
depression or other psychiatric
(mental) conditions may include
thoughts of harming yourself or
committing suicide. It is possible that
these symptoms may continue or
increase until the full antidepressant
effect of your medicine becomes
apparent.
ASK YOUR DOCTOR IF YOU HAVE ANY
QUESTIONS ABOUT WHY MOVOX HAS
BEEN PRESCRIBED FOR YOU.
Your doctor may have prescribed
Movox for another reason.
MOVOX IS NOT APPROVED FOR USE IN
CHILDREN AND ADOLESCENTS

Summary of Product characteristics

MOVOX

_Fluvoxamine maleate _

PRODUCT INFORMATION

NAME OF THE MEDICINE 
Active ingredient: 
Fluvoxamine maleate 
Chemical name:  
(E)-5-methoxy-4
/-trifluoromethylvalerophenone 0-2-aminoethyloxime maleate 
Structural formula: 

Molecular weight: 
434.4    

CAS Registry No. 
61718-82-9 
DESCRIPTION 
Fluvoxamine maleate is a white to slightly off-white, odourless, crystalline powder,
sparingly soluble in 
water, freely soluble in ethanol and chloroform,
practically insoluble in diethylether.  It has a partition 
coefficient (n-octanol/water, own pH) P = 38.7. 
Fluvoxamine is a member of a class of antidepressant agents
known as selective serotonin reuptake 
inhibitors (SSRI).  It is chemically unrelated to the tricyclic
antidepressants, and to other serotonin reuptake 
inhibitors as it is a monocyclic compound. 
MOVOX (fluvoxamine maleate) is available in 50 mg and 100
mg white, film-coated, scored tablets.  The 
inactive ingredients are: 
mannitol, starch - maize, starch - pregelatinised
potato, sodium stearylfumarate, 
silica - colloidal anhydrous, hypromellose, macrogol 6000, talc,
titanium dioxide. 
PHARMACOLOGY 
PHARMACODYNAMICS 
Fluvoxamine has two isomeric forms: an E isomer which is
pharmacologically active, and a Z isomer which 
is non-active.  MOVOX tablets contain only the E isomer. 
The mechanism of action of fluvoxamine is believed to be related to its ability to selectively inhibit 
presynaptic reuptake of serotonin, and
thus increase the serotonin concentrations within the synaptic cleft.

This is accompanied by minimal interference with the noradrenergic
and dopaminergic processes. 

· 
C
4
H
4
O
4

MOVOX – Product Information  

2 
Unlike tricyclic antidepressants, fluvoxamine has
limited affinity for alpha adrenergic, beta adrenergic, 
histaminergi